8-K current report · filed Oct 27, 2026

Amgen (AMGN) 8-K Current Report: October 27, 2026

Item 5.02Item EX-99.1AMGN overview

Short answer

Amgen (AMGN) filed an 8-K current report with the SEC on October 27, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). David W. Gibbs appointed director effective October 26, 2026, expanding the Board to 13 directors.

Amgen 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • David W. Gibbs appointed director effective October 26, 2026, expanding the Board to 13 directors
  • Board remains highly independent: 12 of 13 directors independent
  • Gibbs joins Audit and Compensation and Management Development committees
  • Standard compensation includes $115,000 annual cash retainer and $12,500 committee retainer, prorated for 2026
  • Pro-rated 7/12 equity award based on the $220,000 annual restricted-stock-unit grant; no related-party transactions disclosed

Item EX-99.1 · Exhibit EX-99.1

  • David W. Gibbs appointed immediately to Amgen’s Board, expanding oversight and consumer-brand expertise
  • Gibbs joins Audit Committee and Compensation and Management Development Committee
  • Board expands to 13 directors, with 12 independent members
  • Former Yum! Brands CEO from 2020 to 2025, offering experience in digital transformation and global customer engagement

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Amgen 8-K filings

Get the next AMGN 8-K as it lands

Follow AMGN for push alerts, or ask the research agent what this filing means.